95 results about "Oxaliplatin" patented technology

The invention discloses application of a target protein circPIAS1-108aa inhibitor combined with oxaliplatin in preparation of a medicine synergistic composition for treating cancers, the specific action mechanism of circPIAS1-108aa in colon cancer treatment is found for the first time, and further research shows that by using siRNA to knock down circPIAS1-108aa, colon cancer cell proliferation can be remarkably inhibited, and the effect of treating the colon cancer can be achieved. Furthermore, the target spot protein circPIAS1-108aa inhibitor can be used for enhancing the treatment effect of the oxaliplatin. Therefore, when the circPIAS1-108aa expression is inhibited in a targeted manner and the oxaliplatin is combined for use, the circPIAS1-108aa can be obviously used for preventing and treating cancers, the dosage and toxic and side effects of the oxaliplatin are reduced, and a new synergistic strategy is provided for tumor treatment.

The invention is applicable to the technical field of biological medicines, provides application of a natural compound of a targeted colon cancer drug resistance related protein, and particularly relates to application in preparation of drugs for preventing or treating colon cancer. According to the invention, a natural small molecule compound neohesperidin dihydrochalcone targeting the colon cancer drug resistance related protein TAGLN is screened out, and a new scheme is provided for reversing colon cancer drug resistance, so that the situation that no drug is available to the target spot is solved. Secondly, the invention also provides a scheme for combined use of neohesperidin dihydrochalcone and oxaliplatin, the scheme can significantly enhance the killing effect of oxaliplatin on drug-resistant colon cancer, and a new choice is provided for clinical treatment of colon cancer.

The present application relates to a kind of pH / H2O2 dual-response drug-loaded hydrogel and its preparation method and application, by ε-polylysine derivative as antitumor active ingredient, with oxidized dextran through Schiff base reaction crosslinking rapid gelation. While using 2-formylphenyl boronic acid covalently package CD73 small molecule inhibitor APCP. ε-polylysine derivative has oncolytic activity, can induce ICD and promote the infiltration of immune cells in tumor cells. CD73 small molecule inhibitor APCP can block extracellular CD39-CD73-adenosine pathway, reduce the level of immunosuppressive metabolite adenosine in tumor tissue, so as to activate the infiltrated immune cells, restore its anti-tumor function. The hydrogel of ε-polylysine derivative and APCP co-delivery synergistically inhibits the effect of tumor growth, and its curative effect is greater than the treatment effect of single drug, and is superior to positive control drug oxaliplatin (OXA). The pH / H2O2 dual-response hydrogel is rapidly gelled, and has good biological safety under mild reaction conditions.

The invention discloses application of circFAM126A in preparation of a medicine for reversing oxaliplatin resistance of gastric cancer, and belongs to the technical field of molecular biology. According to the application disclosed by the invention, by constructing a lentivirus for targeted interference of novel circFAM126A and transfecting gastric cancer cells, it is proved that the lentivirus carrying a specific interference sequence can stably knock down circFAM126A expression in the gastric cancer cells, the drug resistance of the gastric cancer cells to oxaliplatin is effectively reversed, the tumor cell death effect induced by chemotherapeutic drugs is remarkably enhanced, and the tumor cell death effect is remarkably improved. Meanwhile, the proliferation and clone formation capability of gastric cancer cells is inhibited. Meanwhile, it is found that circFAM126A is highly expressed in oxaliplatin-resistant gastric cancer cells and is in positive correlation with poor prognosis of gastric cancer patients, a detection reagent aiming at circFAM126A can be used for auxiliary diagnosis of gastric cancer prognosis conditions, and the drug resistance degree of the gastric cancer cells to oxaliplatin can be evaluated by detecting the expression level of circFAM126A.

This invention discloses a composite nanozyme that enhances the clinical efficacy of oxaliplatin, its preparation method, and its application. The composite nanozyme consists of indium ruthenium nanozyme and an iliximab embedding and anchoring layer. The indium ruthenium nanozyme consists of indium ruthenium nanoparticles and a carbon-nitrogen framework, with the indium ruthenium nanoparticles loaded on the surface and within the pores of the carbon-nitrogen framework. The iliximab embedding and anchoring layer consists of a dithiol polyethylene glycol coating layer and iliximab. Preparation method: ZIF-8 is prepared by co-precipitation of zinc salt methanol solution and 2-methylimidazole methanol solution, followed by calcination to obtain the carbon-nitrogen framework. The carbon-nitrogen framework dispersion is then stirred in an oil bath with indium nitrate solution and ruthenium trichloride solution to prepare a nanozyme precursor, followed by calcination to obtain indium ruthenium nanozyme. The indium ruthenium nanozyme is dispersed in a dithiol polyethylene glycol solution, and iliximab solution is added dropwise. The resulting solid product is then dried. This invention can solve problems such as strong drug tolerance, insufficient intracellular accumulation, and severe tumor immunosuppression in oxaliplatin treatment.

The present invention relates to methods of treating B-cell proliferative disorders, e.g., primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL), by administering glofitamab in combination with gemcitabine and oxaliplatin. Further the invention related to an optimized corticosteroid prophylaxis for glofitamab resulting in lower incidence of cytokine release syndrome (CRS).

The application belongs to the technical field of biological medicine, and provides application of a natural compound targeting colon cancer drug resistance related protein, in particular, application in preparation of a drug for preventing or treating colon cancer; the application screens out a natural small-molecule compound hesperetin dihydrochalcone targeting colon cancer drug resistance related protein TAGLN, and provides a new scheme for reversing colon cancer drug resistance, so as to solve the situation that no drug is available for the target point. In addition, the application further provides a scheme in which hesperetin dihydrochalcone is combined with oxaliplatin, and the scheme can significantly enhance the killing effect of oxaliplatin on drug-resistant colon cancer, thereby providing a new choice for clinical treatment of colon cancer.

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

The invention provides application of combined use of ophiopogonin D and oxaliplatin in preparation of a medicine for treating colorectal cancer. The invention also provides a nano-drug delivery system containing co-assembly of ophiopogonin D and oxaliplatin, and the nano-drug delivery system is prepared by the following steps: by taking ZIF-8, ophiopogonin D and oxaliplatin as raw materials, synthesizing ZIF-8 (at) OPHamp, taking the ZIF-8 (at) OPHamp as a carrier, and taking the ZIF-8 (at) OPHamp as a carrier to prepare the nano-drug delivery system containing co-assembly of ophiopogonin D and oxaliplatin. The invention relates to an OXA nanoparticle (ZOX NPs). The invention also provides a co-assembled nano-drug delivery system containing the hyaluronic acid. According to the invention, ophiopogonin D and oxaliplatin are co-assembled by using a nano traditional Chinese medicine delivery system, and the nano preparation HZOX NPs is successfully synthesized, so that the drug can be more enriched at a tumor site, and the problems of poor stability, poor water solubility, low bioavailability and the like of ophiopogonin D are solved. The nanoparticles are uniform in particle size, high in stability and good in biocompatibility, the nano traditional Chinese medicine delivery system can resist colorectal cancer chemical resistance, and a promising strategy is provided for colorectal cancer treatment.

The present application relates to the application of ocanin in the preparation of anti-tumor drugs, and the ocanin is used in the anti-tumor drugs alone or in combination with 5-fluorouracil, and the concentration of the ocanin used in the preparation of anti-intestinal cancer drugs is 20-500 uMol. It is found that the ocanin can inhibit the growth of intestinal cancer cells in vivo and in vitro, and the naked mice have good tolerance to the natural compound. The ocanin has better anti-intestinal cancer effect than other extracts of goldeneye and devil's needle, and has better anti-cancer effect and smaller toxicity than the current conventional intestinal cancer drug 5-fluorouracil. Therefore, the ocanin can be developed into a new anti-cancer drug.

The invention relates to application of an HOXB9 inhibitor in a medicine for reversing oxaliplatin resistance of gastric cancer, and belongs to the field of biological medicine. The invention discloses for the first time: HOXB9 is remarkably high in expression and is positively correlated with poor prognosis in tissues of patients with gastric cancer, which are poor in curative effect after chemotherapy containing oxaliplatin; by constructing an oxaliplatin drug-resistant gastric cancer cell strain and a patient-derived organ model, the HOXB9 is proved to specifically mediate the survival of the drug-resistant cell strain by activating a focal adhesion signaling pathway (p-FAK / AKT), and the HOXB9 is irrelevant to cell proliferation. Aiming at the mechanism, shRNA nucleic acid molecules (SEQ ID NO: 1-2) targeting HOXB9 are provided, and drug-resistant cell strains can be selectively killed through lentiviral vector delivery, so that the drug-resistant cell IC50 is reduced by more than 50%, the apoptosis rate is increased by 3 times, and the chemotherapy resistance of organoids is reversed. The invention provides a brand-new target spot and a treatment scheme for overcoming the drug resistance of oxaliplatin for gastric cancer.

This invention provides biomimetic nanopharmaceuticals for mitochondrial dysfunction, methods for producing the same, and applications. [Solution] The biomimetic nanodrug comprises an RGD-engineered exosome as a carrier, decalinium chloride modified on the surface of the carrier, and oxaliplatin encapsulated inside the carrier. The biomimetic nanodrug of the present invention (OXA@Exo-RD) protects cargoes that induce mitochondrial dysfunction in the blood circulation process, sequentially increasing the accumulation of mitochondria in the cargoes by targeting them. Cargo 1 (DQA) induces oxidative stress, triggering mitochondrial-mediated apoptosis and mitochondrial dysfunction, while cargo 2 (OXA) disrupts mitochondrial DNA and inhibits the initiation of DNA repair, thereby improving chemotherapy resistance. Both cargoes synergistically overcome CRC drug resistance and inhibit its migration.

The application discloses application of pachymic acid B in preparation of a medicine for preventing peritoneal metastasis of gastric cancer and a medicine composition thereof. The pachymic acid B is chemically named as 3-O-acetyl-16alpha-hydroxydehydrotrametenolic acid. The in-situ transplantation peritoneal metastasis model of the gastric cancer proves that intraperitoneal injection of the pachymic acid B can significantly reduce the number of peritoneal metastasis nodules and tumor load, the prevention effect is equivalent to that of oxaliplatin, and there is no obvious organ toxicity. Further experiments prove that the pachymic acid B can up-regulate the mRNA and protein expression levels of SPRED2 genes in peritoneal tissues of the gastric cancer, and plays a role in a time-dose dependent manner. The pachymic acid B provided by the application is administered by intraperitoneal injection, can be prepared into a suspension containing sodium carboxymethyl cellulose, and is especially suitable for perioperative administration of gastric cancer primary focus resection. Compared with the prior art, the application has the advantages of clear composition, novel action mechanism, high safety, simple operation, strong accessibility and the like.

The present application relates to the role of UCK1 in promoting the sensitization of colorectal cancer treatment. The present application discloses the key role of UCK1 in the treatment of colorectal cancer. Clinical samples show that the expression of UCK1 in tumor tissues is reduced, and its low expression is related to chemotherapy resistance and poor prognosis. Studies have shown that UCK1 enhances the efficacy of oxaliplatin (OXA) by regulating metabolic pathways, and promotes B cell activation, thereby recruiting CD8 + T cells, and strengthens anti-tumor immunity. UCK1 overexpression can significantly improve OXA sensitivity and produce a synergistic effect with anti-PD-1 therapy. The present application proposes a new strategy centered on activating UCK1, providing a theoretical basis and application prospect for improving the response of colorectal cancer chemotherapy and immunotherapy.

The application relates to a pharmaceutical application technology, in particular to application of gallic acid in preparation of a medicine for preventing or treating peripheral neuropathy. The peripheral neuropathy is acute peripheral neuropathy caused by using a chemotherapy drug, oxaliplatin. The gallic acid has a protective effect on acute peripheral nerve toxicity of mice induced by oxaliplatin. The medicine, gallic acid, can be used as an adjuvant of a chemotherapy drug for cancer treatment, and has a significant alleviating effect on nerve toxicity caused by chemotherapy.

The invention discloses application of ginsenoside Rg1 in preparation of a product for treating oxaliplatin-induced liver injury, and belongs to the technical field of medicines. Experimental verification shows that after ginsenoside Rg1 is administrated, the survival rate of HL-7702 human hepatocytes induced by oxaliplatin is increased, the content of transaminase indexes AST and ALT in the cells is obviously reduced, the content of active oxygen is obviously reduced, and the condition of mouse liver injury can be obviously improved. The experimental results show that the ginsenoside Rg1 can improve the liver injury induced by oxaliplatin, and a new technical thought is provided for preparing the product for treating the liver injury induced by oxaliplatin.

The invention belongs to the technical field of biological medicine, and particularly relates to application of lovastatin combined with DHCR7 inhibitor AY9944 in preparation of medicine for treating colorectal cancer. The DHCR7 protein expression in the drug-resistant tumor tissue is obviously improved compared with that of normal tumor cells, and verification finds that the DHCR7 inhibitor AY9944 can specifically inhibit the drug resistance of colorectal cancer cells generating drug resistance, and further finds that when AY9944 and lovastatin are combined for use at a specific concentration ratio, the drug resistance of the colorectal cancer cells generating drug resistance can be inhibited, and the drug resistance of the colorectal cancer cells generating drug resistance can be inhibited. The two can play an obvious synergistic effect, so that the sensitivity of intestinal cancer cells to oxaliplatin is more effectively improved. Therefore, the combined medication mode provided by the invention can provide a new strategy reference for clinically overcoming the chemotherapy resistance of colorectal cancer.

The invention provides a gel emplastrum for treating oxaliplatin peripheral neurotoxicity and a preparation method, and relates to the field of traditional Chinese medicine, the gel emplastrum comprises a backing layer, an emplastrum layer and an anti-sticking layer; the paste layer is a gel layer formed by traditional Chinese medicine extract and a matrix for loading the traditional Chinese medicine extract; the traditional Chinese medicine extract is prepared from a traditional Chinese medicine composition; the traditional Chinese medicine composition comprises astragalus membranaceus, angelica sinensis, vinegar rhizoma sparganii, vinegar curcuma zedoary, cassia twig, achyranthes bidentata and pheretima in a mass ratio of 6: 3: 2: 2: 2: 4: 2. The matrix comprises a framework material, a cross-linking agent, a cross-linking regulator, a thickening agent, a humectant, a complexing agent, pure water, a preservative, a penetration enhancer, a thermal inductance regulator and a high-performance emulsifying thickening agent. The problems that in the prior art, a formula for promoting blood circulation to remove blood stasis is inconvenient to use in a soaking and washing main use mode, the patient compliance is poor, the speed of medicine entering the body of a patient is not easy to control, the blood concentration in the body of the patient is difficult to maintain stably, and the peripheral neurotoxicity treatment progress is difficult to control can be solved.

The present invention addresses the problem of providing: an anti-CLDN4 / anti-CD137 bispecific antibody used in combination with a platinum-based drug for treatment of a target cancer; a pharmaceutical composition comprising said bispecific antibody; and a cancer treatment method involving administering, to a subject, an anti-CLDN4 / anti-CD137 bispecific antibody and a platinum-based drug.　In this invention, in a mouse bearing human CLDN4-expressing mouse cancer cells, the combined use of an anti-CLDN4 / anti-CD137 bispecific antibody and oxaliplatin exhibited a significant antitumor effect compared to the case of administering the anti-CLDN4 / anti-CD137 bispecific antibody or oxaliplatin alone. Furthermore, in a mouse bearing human CLDN4-expressing mouse cancer cells, an antitumor effect more effective than double therapy was confirmed in triple therapy in which an anti-CLDN4 / anti-CD137 bispecific antibody is additionally used with double therapy of oxaliplatin and an anti-VEGFR antibody. These results suggest that the combination of an anti-CLDN4 / anti-CD137 bispecific antibody and a platinum-based drug is effective in treatment of a CLDN4-expressing cancer.

The invention relates to a thermo-sensitive hydrogel drug sustained-release stent for jointly loading a hypotensive drug and a chemical / immunotherapy drug, which is prepared from a thermo-sensitive material and loads three drug components, namely losartan, oxaliplatin and an immune checkpoint inhibitor. The temperature-sensitive hydrogel can form gel in situ under the triggering of body temperature, and meanwhile, the acting time of the medicine on a target part is prolonged. The antihypertensive drug losartan potassium can reduce tumor interstitial substances, reduce tumor solid stress, relieve vascular compression in tumors and improve tumor hypoxia. Meanwhile, the chemotherapeutic drug oxaliplatin can induce tumor immunogenic cell death, and the tumor immunosuppressive microenvironment is effectively relieved. The immune checkpoint inhibitor can be used for accurately blocking the combination of the PD-L1 and the PD-1 and activating the T cell mediated anti-tumor immune response. According to the present invention, the potent anti-tumor immune response can be triggered, the excellent tumor inhibition effect can be achieved, the strong far-end effect can be even induced, and the growth of the far-end tumor can be effectively inhibited.

A pharmaceutical use of a pharmaceutical composition containing platinum drugs or platinum drug co-crystals as main active substances in preventing or treating immunological diseases such as rheumatoid arthritis, and other diseases. The platinum drugs mainly refer to oxaliplatin, and the platinum drug co-crystals mainly refer to carboplatin co-crystals or oxaliplatin co-crystals. Further disclosed is a method using platinum drugs or platinum drug co-crystals, either alone or in combination with at least one additional therapeutic agent or adjuvant therapy agent.

The invention provides application of ursodesoxycholic acid in preparation of a medicine for treating peripheral neuropathy. The ursodesoxycholic acid provided by the invention can promote the recovery of sciatic nerve function indexes after the sciatic nerve of a mouse is cut off, and improve the electroneurographic signal conduction function of an injured part; meanwhile, the UDCA can also relieve oxaliplatin-induced ischiadic nerve signal transduction disorder of mice and related crymodynia sensitive symptoms. In addition, the invention further reveals that the relieving effect of the UDCA on the peripheral neuropathy does not depend on promoting Schwann cell migration. According to the discovery, the application value of the UDCA in treating peripheral neuropathy caused by multiple factors is expanded, and a new strategy is provided for clinical treatment of the UDCA.

The invention belongs to the technical field of intelligent drug delivery control, and particularly discloses a colon tumor drug delivery method and system based on AI control, and the method comprises the steps: collecting and preprocessing whole genome sequencing, radiomics, clinical pathology and historical drug treatment response data of a patient, extracting tumor image features, and carrying out drug delivery. The method comprises the following steps: screening oxaliplatin response related gene mutation markers by combining Lasso regression with a Cox model, forming feature vectors by t-SNE dimensionality reduction clinical pathological data, training a model through a gradient boosting tree and deep neural network fusion algorithm, taking oxaliplatin response probability as output, and recommending an FOLFOX scheme or an FULV scheme according to a model result. According to the method, precision and individuation of chemotherapy are achieved, unnecessary toxic and side effects are reduced, the life quality and lifetime of a patient are improved, and the problems that in the prior art, dependence on experience, single data dimension, no dynamic adjustment mechanism and poor stability are solved. Therefore, the problems of low response rate of oxaliplatin and obvious side effect are solved.

The application discloses application of a small-molecule compound LZ-A4 in preparation of a preparation or a medicine for treating malignant tumors. 19 H 11 Cl2N3O3S, which can promote LGMN degradation in malignant tumor cells, inhibit tumor cell proliferation, and inhibit macrophage polarization to M2 type. The application proves through research on a colorectal cancer mouse transplanted tumor model that LZ-A4 alone can effectively inhibit the progression of colorectal cancer, and after being combined with a colorectal cancer first-line chemotherapy medicine oxaliplatin, the tumor volume can be further reduced. Meanwhile, LZ-A4 can inhibit M2 type polarization of macrophages in a tumor microenvironment in vivo, promote infiltration of cytotoxic T cells, reshape the tumor microenvironment, and activate anti-tumor immunity. In addition, A4 performs well in terms of toxic side effects, and after being combined with the chemotherapy medicine, the mouse weight is not further reduced.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a pharmaceutical composition containing atractylenolide, a preparation method and application, the pharmaceutical composition takes lipidosome as a carrier, and comprises lipidosome carrier components such as atractylenolide, oxaliplatin, phospholipid, cholesterol and the like and specific auxiliary components. The pharmaceutical composition is prepared by adopting a film dispersion-ultrasonic homogenization method, the water solubility of the atractylenolide is effectively improved, the bioavailability of the medicine and the stability of the preparation are improved, through the synergistic effect of the atractylenolide and the oxaliplatin, the chemotherapy-related toxic and side effects are reduced while the anti-tumor curative effect is enhanced, and the pharmaceutical composition is suitable for clinical application. The compound can be used for preparing anti-tumor drugs, and a novel efficient and low-toxicity drug scheme is provided for tumor treatment.

The application belongs to the field of new adjuvants and new dosage forms of pharmaceutical preparations, and particularly relates to a type I and type II immunogenic cell death inducer ion pairing engineered nanoassemblies as well as construction and application thereof. The nanoassemblies are composed of type I ICD inducers, type II ICD inducers, hydrophobic auxiliary counterions and amphiphilic lipid ion pairing. The type I ICD inducer is selected from mitoxantrone, doxorubicin, oxaliplatin or cyclophosphamide; the type II ICD inducer is selected from hypericin; and the hydrophobic auxiliary counterion is selected from cholesteryl sodium sulfate, cholic acid, deoxycholic acid, chenodeoxycholic acid, lithocholic acid, glycolcholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid lysine derivative, oleanolic acid and ursolic acid. The type I and type II ICD inducers are combined in the application, and have a synergistic tumor treatment effect.

This invention relates to the fields of microbiology and biomedicine, and particularly to a strain of *Lactobacillus brittlemi* SYSU-32 and its application in tumor treatment. This invention cultured and isolated a strain of *Lactobacillus brittlemi* (SYSU-32). Limosilactobacillus pontis SYSU-32 was deposited on September 15, 2025, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 35919. This strain can increase CD8+ in the tumor microenvironment. + Infiltration of T cells and cytotoxic T cells inhibits the progression of colorectal cancer. Furthermore, the combination of *Lactobacillus bridgedii* SYSU-32 with the chemotherapy drug oxaliplatin enhances the pro-apoptotic effect of oxaliplatin, further inhibiting tumor progression and metastasis.

The invention discloses a functional phosphorylation modification site screening method based on base editing, which is used for accurately identifying functional phosphorylation modification sites. According to the method, a cell line (such as human gastric cancer cells AGS / HGC27) for stably expressing ABE is constructed, an sgRNA library (containing 39 and 689 sites) covering phosphorylation sites of a whole genome is designed, screening is carried out under the conditions of oxaliplatin and the like, and the technical problem that more than 95% of phosphorylation sites are unknown in function is solved. According to the method, key sites (such as WEE1 S53) related to gastric cancer chemotherapy drug resistance are successfully recognized, the synergistic effect of oxaliplatin and WEE1 inhibitor combination is verified through experiments, and an innovative platform is provided for disease mechanism research and drug development.

The application discloses application of a CDK4 / 6 inhibitor combined with oxaliplatin in preparation of a treatment drug for chemotherapy-resistant colorectal cancer. The combined use of the CDK4 / 6 inhibitor combined with oxaliplatin has excellent therapeutic effect on locally advanced rectal cancer which is resistant to a first-line chemotherapy scheme, can overcome the drug resistance of the rectal cancer patient to the chemotherapy drug, so that the tumor proliferation is inhibited, and the apoptosis of the cancer cell is promoted. The application provides a combined drug treatment scheme for neoadjuvant therapy of locally advanced rectal cancer chemotherapy resistance, can achieve the purpose of effectively treating or assisting in treating the rectal cancer, and provides a new way for treating, diagnosing or predicting the rectal cancer patient.

The application discloses application of a Blautia in preparation of a drug for enhancing sensitivity of colorectal cancer to oxaliplatin, B-CM can significantly enhance OXa cytotoxicity on drug-resistant colorectal cancer cells, inhibit proliferation, clone formation, migration and invasion ability. Combination therapy can synergistically induce apoptosis, although the expression of MDR1 in drug-resistant cells is up-regulated, but the combination of B-CM and OXa can significantly reduce the mRNA and protein levels. In vivo experiments show that B-CM enhances the tumor inhibition effect of OXa, which is related to the reduction of the expression of Ki-67 and MDR1 in tumor tissues. Further, it can be shown that the soluble factor derived from Blautia can reverse the drug resistance of colorectal cancer to oxaliplatin by down-regulating MDR1 and inhibiting epithelial-mesenchymal transition. This shows that Blautia-derived metabolites are a promising new adjuvant strategy to overcome chemotherapy resistance of colorectal cancer.